CD38-Directed Therapies for Management of Multiple Myeloma

Abstract

The survival outcomes for multiple myeloma have improved several-fold in the past two decades, primarily due to the introduction of therapies with novel mechanisms of action including immunomodulatory agents, proteasome inhibitors, stem cell transplant and monoclonal antibodies in the schema of therapy. Antibody-based therapies targeting the surface marker CD38, namely daratumumab and isatuximab, have emerged as being highly effective as single agents as well as in combination regimens for both newly diagnosed and relapsed settings. Herein, the authors summarize the most recent data with both the current and emerging CD38-directed therapies in multiple myeloma.

Keywords:

• multiple myeloma
• daratumumab
• isatuximab
• CD38
• bispecific antibody
• antibody drug conjugate

Disclosure

H.H., M.H and A.K. have no conflicts to declare. S.Z.U. – Research funding: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda; Consulting: Amgen, BMS, Celgene, EdoPharma, GSK, Janssen, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio; Speaking fees: Amgen, BMS, Janssen, Sanofi; Personal fees: Gilead, Genentech, outside the submitted work.